Acrivon Therapeutics Company Profile - aVenture Research
Acrivon Therapeutics is a precision oncology drug developer built on its AP3 proteomics platform, which generates proprietary OncoSignature companion diagnostics. Its lead program is ACR-368, a CHK1/2 inhibitor, and its internally developed candidates are ACR-2316, a dual WEE1/PKMYT1 inhibitor, and ACR-7280, a CDK11 inhibitor in IND-enabling studies.
The OncoSignature tests link a patient's tumor-driving mechanisms to a drug's mode of action, matching therapies to patients likely to benefit independent of genetic tumor alterations. Acrivon applies this approach to oncology targets that lack simple single gene driver mutations or synthetic lethal contexts.
Acrivon Therapeutics is a precision oncology drug developer whose AP3 proteomics platform generates proprietary OncoSignature diagnostics to identify likely responders.